Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Beige adipocytes in white adipose tissue (WAT) share similar functions as brown adipocytes by converting lipids into heat through thermogenesis, while lipolysis is considered as a prerequisite for the activation of non-shivering thermogenesis. β3-adrenergic receptor (β3-AR) agonist CL316,243 (CL) and cold exposure are known to enhance lipolysis and beiging of WAT in a protein kinase A (PKA)-dependent manner, while the role of PKA-independent pathways involved is still poorly understood. Here, we show that the exchange protein directly activated by cAMP 1 (Epac1), a downstream target of cAMP, mediates β3-AR activation to modulate thermogenesis and lipolysis in a PKA-independent manner. Upon CL treatment or cold exposure, both thermogenic and lipolytic responses were compromised in Epac1-deficient mice, as evidenced by reduced oxygen consumption, less beige adipocytes, lower body temperature, and decreased circulating glycerol. Additionally, in vitro beige adipogenesis with or without cAMP analog treatment was significantly impaired in Epac1-deficient mice. Mechanistically, reduced total and phosphorylated p38γ and decreased induction of nuclear factor activated in T cells 5 (NFAT5) were observed in Epac1-deficient mice, which may contribute to the defective beiging of WAT. However, WAT of wildtype and Epac1-deficient mice showed no significant induction difference in phosphorylation of hormone-sensitive lipase at PKA and AMP-activated protein kinase sites with PKA activator, and in vitro beige adipogenesis was not altered in Epac1-deficient mice in response to PKA activation, indicating that Epac1 mediates lipolysis and beige adipogenesis in a PKA-independent manner. Taken together, Epac1 mediates β3-AR-induced beiging and lipolysis of WAT via the p38γ-NFAT5 axis in a PKA-independent manner.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12238815PMC
http://dx.doi.org/10.1042/CS20256710DOI Listing

Publication Analysis

Top Keywords

epac1-deficient mice
20
pka-independent manner
16
epac1 mediates
12
thermogenesis lipolysis
12
beige adipogenesis
12
white adipose
8
adipose tissue
8
p38γ-nfat5 axis
8
axis pka-independent
8
beige adipocytes
8

Similar Publications

Background: Idiopathic Pulmonary Fibrosis (IPF) is marked by progressive lung scarring with no existing cure, emphasizing the need for new therapeutic targets. Current evidence suggests that cyclic adenosine monophosphate (cAMP) mitigates lung fibroblast proliferation the PKA pathway, but the impact of Epac1, a cAMP-activated protein, on IPF remains unexplored.

Objective: To investigate the role of Epac1 in IPF progression.

View Article and Find Full Text PDF

Beige adipocytes in white adipose tissue (WAT) share similar functions as brown adipocytes by converting lipids into heat through thermogenesis, while lipolysis is considered as a prerequisite for the activation of non-shivering thermogenesis. β3-adrenergic receptor (β3-AR) agonist CL316,243 (CL) and cold exposure are known to enhance lipolysis and beiging of WAT in a protein kinase A (PKA)-dependent manner, while the role of PKA-independent pathways involved is still poorly understood. Here, we show that the exchange protein directly activated by cAMP 1 (Epac1), a downstream target of cAMP, mediates β3-AR activation to modulate thermogenesis and lipolysis in a PKA-independent manner.

View Article and Find Full Text PDF

In the bullous autoimmune disease pemphigus vulgaris (PV), autoantibodies directed mainly against desmoglein 1 (Dsg1) and Dsg3 cause loss of desmosomal adhesion. We recently showed that intracellular cAMP increase by the phosphodiesterase 4 inhibitor apremilast was protective in different PV models. Thus, we here analyzed the involvement of the cAMP effector exchange factor directly activated by cAMP1 (Epac1).

View Article and Find Full Text PDF
Article Synopsis
  • Idiopathic Pulmonary Fibrosis (IPF) is a lung disease characterized by progressive scarring and currently lacks a cure, prompting the need for new therapeutic targets such as the cAMP pathway, particularly the protein Epac1.* -
  • The study aimed to understand how Epac1 contributes to IPF progression by examining lung samples from IPF patients and preclinical models, alongside testing the effects of inhibiting Epac1 using a specific pharmacological agent, AM-001.* -
  • Results showed that Epac1 levels were elevated in IPF tissue and fibroblasts, and inhibiting Epac1 led to reduced fibroblast proliferation and profibrotic signaling, indicating its potential role as a therapeutic target
View Article and Find Full Text PDF

Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress.

Cardiovasc Res

October 2019

INSERM UMR-1048, Institut des Maladies Métaboliques et Cardiovasculaires, 1 avenue Jean Pouhlès, Toulouse, France.

Aims: Recent studies reported that cAMP-binding protein Epac1-deficient mice were protected against various forms of cardiac stress, suggesting that pharmacological inhibition of Epac1 could be beneficial for the treatment of cardiac diseases. To test this assumption, we characterized an Epac1-selective inhibitory compound and investigated its potential cardioprotective properties.

Methods And Results: We used the Epac1-BRET (bioluminescence resonance energy transfer) for searching for non-cyclic nucleotide Epac1 modulators.

View Article and Find Full Text PDF